Benitec Biopharma (BNTC) vs Scribe Therapeutics (SCTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Scribe Therapeutics is the larger company by market cap ($332.6 million vs $313.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTC | SCTX |
|---|---|---|
| Share price | $8.99 | $17.57 |
| Market cap | $313.60M | $332.63M |
| 1-day change | -0.11% | +7.59% |
| YTD return | -33.26% | — |
| 1-year return | -34.76% | — |
| 5-year return | -85.27% | — |
| EPS (TTM) | $-0.98 | $-4.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.76 | $39.60 |
| 52-week low | $8.52 | $13.50 |
| Distance from 52-week high | -46.36% | -55.63% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +170.63% | +224.42% |
| Average volume | 150.34K | 356.27K |
| Shares outstanding | 34.88M | 18.93M |
| Employees | 24 | 82 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Benitec Biopharma
BNTC stock →Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.
Healthcare · Biotechnology · 24 employees
About Scribe Therapeutics
SCTX stock →Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.
Healthcare · Biotechnology · 82 employees
BNTC vs SCTX FAQ
Which is bigger, Benitec Biopharma or Scribe Therapeutics?
Scribe Therapeutics (SCTX) is larger, with a market capitalization of $332.63M compared with $313.60M for Benitec Biopharma (BNTC).
Are Benitec Biopharma and Scribe Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.